One Health Group Welcomes Mr. Carl Eckstein as a New Board Member

Mr. Carl Eckstein joins the Board of Directors of One Health Group (OHG), bringing his Corporate, Consulting and Fund Management expertise. He has an impressive track record of success in early-stage venture investment, with multiple successful exits.

About OHG

OHG, a medical technology innovator, is thrilled to announce the appointment of Mr. Carl Eckstein as a member if its Board of Directors, 28^th March 2024.

OHG is on a mission to bring breakthrough health diagnostics, therapeutics, monitoring, screening, and advanced analytics to market. Driven by seeking solutions to preventing needless animal and human illnesses, often attributed to a lack of health data, OHG has developed a patented mobile health assessment technology that uses intelligent sensors and artificial intelligence to provide personalized, context-based real-time health information. OHG’s goal is to provide a unique health platform that integrates animal, human, and environmental data, which are intrinsically linked.

OHG’s Decision to appoint Mr. Eckstein to its Board of Directors

Carl has both technical and financial industry expertise via being a technical solution developer for many years as well as co-founding and leading a successful VC firm, Next Generation Capital Fund I and Fund II.

Carl co-founded, and is leading a new VC firm, and has agreements with multiple major US academic institutions. They are working with him to fund start-ups that spinout of those universities.  Presently, Carl is raising the first fund.

Carl has personally invested in OHG and has also brought several other high profile investors. He is a trusted resource who he is passionate / bullish about, and believes in OHG.  He is also well in tune with Michael Stanfield, Mark Frazer, Jeremey Junnila, and Albert Di Rienzo, having worked with all of us over the past couple of years. He has been a great sounding board concerning business models, funding, go-to-market, and much more.

Mr. Eckstein’s Background

Venture capitalist, Mr. Eckstein served as a founder and Managing Director of Next Generation Capital Fund I and Next Generation II venture capital funds; participated in 22 investments, mergers and acquisitions, and replaced the CEOs of three struggling portfolio companies, steering them to successful exits. Initially for IBM and later as a Manager at Price Waterhouse, a principal with Arthur Young and through his own firm, Mr. Eckstein provided professional consulting and technology services to over 250 corporations, federal government, and not-for-profit organizations.

Among his technology accomplishments, Mr. Eckstein designed the first fully integrated ERP systems for manufacturing for AO Smith, the first Wiki for the Federal Communications Commission, and helped develop the first GIS system for transportation routing. He has lectured at several universities on the investment in early-stage companies. Mr. Eckstein holds a degree in Microbiology from Ohio State University.

Currently, aside from serving on the Board of One Health Group, Mr. Eckstein is Chairman and Director of Strategic Initiatives of Gunston Ventures, Inc., a firm investing in early-stage technology firms solving high value problems with high-value solutions.

Mr. Eckstein’s and One Health Group

Mr. Eckstein became familiar with One Health Group in 2018. And he became an early investor for the following five reasons:

1. Leadership and Team:  Albert Di Rienzo is a proven leader in medical device product development with a reputation for high integrity and industry respect.  His team was lean, but of high quality.
2. Platform Technology with Heavy Patent Protection:  One Health Group currently has 72 patents – and another 12 pending – related to its ultrawideband radar technology (5G) that can be applied to multiple opportunities, the first of which is companion animal health.
3. Large Markets with Initial Focus on Companion Animals:  One Health Group can provide real-time health monitoring that is unavailable in everyday settings.  For veterinarians and pet parents this permits the monitoring of the health of their patients and pets that have experienced surgery or have chronic health conditions.  For researchers it permits the monitoring of laboratory animals who are part of clinical trials.  Witnessed by the international interest in One Health Group, it is probable that the company will be profitable shortly after initial product production and it will rapidly scale from there.  It currently has many potential customers waiting for its product and service.
4. Continual Service Business Model with High Margins:  Though One Health Group is designed around a device, its business model is a service, with cloud services using analytics and AI on data captured continually via the device and returning results to veterinarians and pet parents as alerts or as desired.
5. Scale:  One Health Group can scale.  Its products and services are needed worldwide.  And it can apply its technology to monitor production animals – cattle, pigs, horses, pigs, sheep, goats and chickens.

After evaluating over 7,000 opportunities as a venture capitalist, Mr. Eckstein believes that One Health Group is the best early-stage opportunity that he has encountered.

View the Press Release here

Communications

Albert J Di Rienzo
One Health Group
+1 315-247-3828
albert.dirienzo@ohgcorp.com
Visit us on social media:
LinkedIn

One Health Group (OHG) Announces New Chief Veterinary Officer

[Cazenovia, NY, April 1st, 2024] – OHG, a medical technology innovator, is thrilled to announce the appointment of Amanda Landis-Hanna, DVM, as its new Chief Veterinary Officer (CVO), effective April 1, 2024. With a proven track record as a changemaker in the veterinary sector, Dr. Landis-Hanna brings a wealth of experience and expertise that will undoubtedly propel OHG to new heights.

OHG is on a mission to bring breakthrough health diagnostics, therapeutics, monitoring, screening, and advanced analytics to market. Driven by seeking solutions to preventing needless animal and human illnesses, often attributed to a lack of health data, OHG has developed a patented mobile health assessment technology that uses intelligent sensors and artificial intelligence to provide personalized, context-based real-time health information. OHG’s goal is to provide a unique health platform that integrates animal, human, and environmental data, which are intrinsically linked.

Responsibilities of the CVO

As our CVO, Dr. Landis-Hanna will:

• Contribute to OHG’s product line requirements in terms of clinical, regulatory, and commercial aspects per her vast experience of such matters.
• Provide strategic leadership in veterinary policy, research, and practice to enhance OHG’s Strategic & Operational Plans and Integrated Product Roadmap.
• Collaborate with government agencies, academia, industry stakeholders, and strategic customers & partners to advance OHG’s long-term business performance.
• Work with the OHG Primary & Advisory Boards as well as Executive & Cross-Functional Leadership to foster a common understanding of clinical and regulatory veterinary matters.
• Advocate for evidence-based understanding of veterinary medicine with internal and external stakeholders.
• Represent and promote OHG at external events related to all veterinary matters.

About Dr. Amanda Landis-Hanna

• Background: Dr. Landis-Hanna holds a Doctorate in Veterinary Medicine from Auburn University. She has 22 years of experience in small animal, mixed animal and exotic medicine; additionally, she has practiced shelter medicine, relief medicine and has worked in both private and corporate practice. She has also worked in research and industry, developing new strategies to solve problems in the veterinary space.
• Previous Roles: Prior to joining OHG, Dr. Landis-Hanna served as Founder of Landis-Hanna Consulting, providing continuing education, content production, and veterinary mentoring. She was the Vice President of Heal House Call Veterinarian, helping veterinarians provide accessible veterinary care by overcoming transportation and financial constraints.  She was the Senior Manager of Veterinary Outreach for PetSmart Charities, managing a grant program, which supported veterinary student training, and student and faculty research grants for 30 major academic institutions in the U.S. and Canada; she served as the senior advisor, spokesperson and representative interfacing with veterinary professional networks, animal welfare professionals, and faculty and researchers to ensure strategic targeting the grant portfolio.  Her first primarily research role was with i4C Innovations, the founder of Voyce, which is a wholly owned subsidiary of OHG.
• Passions for Veterinary Medicine and Veterinary Professionals: Her passions include improving access to veterinary care by decreasing barriers within communities, increasing research and educational opportunities within veterinary medicine, and mental health in the animal care industry.
• Board Appointments: Landis-Hanna is currently serving as Secretary of the Board of the Human-Animal Bond Association (HABA). She is an At Large Board member to RedRover, an animal welfare nonprofit organization.  She also serves as the Board of the North Carolina Veterinary Medical Association (NCVMA).
• Amanda is a co-host for the Veterinary Business Podcast – https://www.veterinarybusinessinstitute.com/hosts/.

Quotes

• Albert Di Rienzo, President: “I’ve had the pleasure of knowing and working with Dr. Landis-Hanna for years, and can’t imagine a more capable, suitable, and engaging person as OHG’s Chief Veterinary Officer. I am absolutely thrilled and honored that she will be a key contributing member of the Company’s executive team.”
• Ken Lambrecht, OHG Advisory Board: “As an advisory board member for the past 3 years with a passion for pet health technology I am looking forward to working with Dr. Amanda with her extensive expertise in pet wearables. Her vast experience in working with veterinarians and other professionals and her enthusiastic attitude will undoubtedly propel OHG forward in their amazing mission.”
• Landis-Hanna: “I am delighted to be joining One Health Group, the maker of innovative products, including Voyce, a biometric monitoring device for animals. I initially joined the team in its initial iteration before the project had a name!  I am thrilled to be working with the amazing team and investors of One Health Group as an advocate of utilizing technology to serve One Health needs, veterinary care challenges, and patients of all species.”

Contact Information

• Amanda Landis-Hanna, DVM; landis.hanna@ohgcorp.com
• https://www.linkedin.com/in/amanda-landis-hanna/

For media inquiries or further information, please contact:

• Albert Di Rienzo, President
• DiRienzo@ohgcorp.com

Formal Strategic Relationship with Alfresa Corporation:

Exclusive Distribution Agreement in Japan and a Significant Investment in OHG

During the last week of December 2023, One Health Group (OHG) and Alfresa Corporation, a multi-billion-dollar leader in the Japanese healthcare industry, entered into a formal strategic relationship by signing an exclusive agreement with OHG to distribute OHG products in Japan.  They will be marketing OHG’s Voyce solution as part of their animal health & wellbeing offerings. 

Furthermore, on 05 January 2024, through Alfresa’s investment fund partner, Alfresa made a significant investment in OHG’s current seed fundraising round, which is affirmation of their commitment to OHG, and belief in its solution offerings. 

  .     

   About OHG

OHG, Inc. is a medical technology innovator with a mission to bring breakthrough health diagnostics, therapeutics, monitoring, screening, and advanced analytics to market.  Driven by seeking solutions to preventing needless animal and human illnesses, often attributable by a lack of health data, OHG has developed a patented mobile health assessment technology that uses intelligent sensors and artificial intelligence to provide personalized, context-based real-time health information.  OHG’s goal is to provide a unique health platform that integrates animal, human, and environmental data, which are intrinsically linked.  For more information, please see: Remote Medical Diagnostics for Animal Health | One Health Group

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceuticals manufacturing, and operating dispensing pharmacies.  Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥ 2.6 trillion for the fiscal year ended March 31, 2023. For more information, please see: https://www.alfresa-hc.com/en/